OSLO, Norway, May 8, 2019 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage biotechnology company
developing immune activators to target hard-to-treat solid tumors,
today announces that it has completed patient enrollment in the
phase Ib/II trial of ONCOS-102 in combination with chemotherapy in
unresectable malignant pleural mesothelioma
(MPM).
The trial consists of a phase Ib safety lead-in part followed by
a randomized, open label phase II part, assessing the combination
of ONCOS-102 and standard of care (SoC) chemotherapy (pemetrexed
and cisplatin) vs SoC chemotherapy alone in first or second/third
line patients with unresectable MPM. In May
2018, Targovax reported no safety issues, strong innate and
adaptive immune activation and 50% disease control rate (DCR) for
the six patients in the phase Ib safety lead-in cohort - see link
to press release here.
The enrollment of 25 patients into the randomized phase II part
of the trial has now been completed, with a total of 31 patients on
the trial who will be evaluated for safety, immune response and
efficacy. There are 20 patients in the experimental arm combining
ONCOS-102 with chemotherapy and eleven patients in the chemotherapy
only control group. The patients in the part I safety cohort form
part of the experimental arm.
The aim of the trial is to assess safety and tolerability,
immunological activation and 6-month overall response rate (ORR) of
the combination of ONCOS-102 and SoC chemotherapy compared to SoC
chemotherapy alone. Data read out is expected around New Year.
Magnus Jäderberg, CMO of Targovax, said: "We
are very pleased to have completed enrollment of our mesothelioma
trial. ONCOS-102 is currently the most clinically advanced
oncolytic virus in this difficult to treat cancer, and therefore a
high priority for us. The randomized ORR and immune data from this
study will indicate whether the ONCOS-102 and chemotherapy
combination gives patients a benefit over chemotherapy. The
clinical and immune data will guide the further development of
ONCOS-102 in mesothelioma."
CONTACT:
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-completed-enrollment-of-oncos-102-trial-in-mesothelioma,c2806118
View original
content:http://www.prnewswire.com/news-releases/targovax-announces-completed-enrollment-of-oncos-102-trial-in-mesothelioma-300845979.html
SOURCE Targovax